<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937907</url>
  </required_header>
  <id_info>
    <org_study_id>2021SPNR001</org_study_id>
    <secondary_id>2019YLYM06</secondary_id>
    <nct_id>NCT04937907</nct_id>
  </id_info>
  <brief_title>Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)</brief_title>
  <acronym>CHXLAS</acronym>
  <official_title>Efficacy and Safety of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of&#xD;
      Hydroxychloroquine in qualified patients with Alport syndrome. The trial will be open-label,&#xD;
      randomized, controlled and will enroll up to 50 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of&#xD;
      Hydroxychloroquine in qualified patients with Alport syndrome. The trial will be open-label,&#xD;
      randomized, controlled and will enroll up to 50 patients.&#xD;
&#xD;
      Patients in the Phase 2 cohort will be randomized 1:1 to either Hydroxychloroquine Cohort or&#xD;
      Comparator Cohort.&#xD;
&#xD;
      All patients in the study will follow the same visit and assessment schedule. Following&#xD;
      randomization on Day 1, patients will be scheduled to be assessed during treatment at Weeks&#xD;
      4, 12, and 24. Patients will not receive study drug during a 24-week withdrawal period&#xD;
      between Weeks 25 and 48. Patients will also be scheduled to be assessed at an in person&#xD;
      follow up visit at Week 36, and 48.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in urinary erythrocyte count(/HP)</measure>
    <time_frame>Baseline to maximum 48 weeks</time_frame>
    <description>To assess the change in urinary erythrocyte count(/HP) from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour urinary protein quantity</measure>
    <time_frame>Baseline to maximum 48 weeks</time_frame>
    <description>To assess the change in 24-hour urinary protein quantity from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary albumin characterization</measure>
    <time_frame>Baseline to maximum 48 weeks</time_frame>
    <description>To assess the change in urinary albumin characterization from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary albumin to creatinine ratio</measure>
    <time_frame>Baseline to maximum 48 weeks</time_frame>
    <description>To assess the change in urinary albumin to creatinine ratio from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary erythrocyte count(urinary sediment analyzer)</measure>
    <time_frame>Baseline to maximum 48 weeks</time_frame>
    <description>To assess the change in urinary erythrocyte count(urinary sediment analyzer) from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in eGFR from baseline</measure>
    <time_frame>Baseline to maximum 48 weeks</time_frame>
    <description>To assess the increase in eGFR from baseline to week 48 for patients receiving active drug, compared to patients in Comparator Cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Baseline to maximum 48 weeks</time_frame>
    <description>Safety will be assessed by monitoring adverse events, physical examinations and clinical laboratory test through 48 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alport Syndrome, X-Linked</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the cohort will receive Hydroxychloroquine(HCQ) throughout the study.Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day for 6 months. During treatment with HCQ, patients also received enalapril(5-10mg qd).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Cohort</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>During treatment with HCQ, Patients randomized to Comparator Cohort only received enalapril(5-10mg qd).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine Sulfate 100 milligram (mg) Tab</intervention_name>
    <description>Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.</description>
    <arm_group_label>Hydroxychloroquine Cohort</arm_group_label>
    <other_name>HCQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benazepril hydrochloride 10 milligram (mg) Tab</intervention_name>
    <description>Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.</description>
    <arm_group_label>Comparator Cohort</arm_group_label>
    <arm_group_label>Hydroxychloroquine Cohort</arm_group_label>
    <other_name>Benazepril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female;&#xD;
&#xD;
          -  Age 3-18 years old;&#xD;
&#xD;
          -  Diagnosis of Alport syndrome by genetic testing (documented mutation in a gene&#xD;
             associated with Alport syndrome, including COL4A3, COL4A4, or COL4A5) or histologic&#xD;
             assessment using electron microscopy;&#xD;
&#xD;
          -  Screening eGFR ≥ 90 mL/min/1.73 m2;&#xD;
&#xD;
          -  ACE inhibitor and/or ARB, the dosing regimen should be stable for at least 4 weeks&#xD;
             prior to screening;&#xD;
&#xD;
          -  No antirheumatic drugs such as hydroxychloroquine have been used;&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, treatment plan, laboratory tests,&#xD;
             and other study procedures;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Causes of chronic kidney disease aside from Alport syndrome (including but not limited&#xD;
             to other heritable disorders leading to chronic kidney disease, diabetic nephropathy,&#xD;
             hypertensive nephropathy, lupus nephritis, IgA nephropathy);&#xD;
&#xD;
          -  Prior exposure to hydroxychloroquine;&#xD;
&#xD;
          -  Ongoing chronic hemodialysis or peritoneal dialysis therapy;&#xD;
&#xD;
          -  Renal transplant recipient;&#xD;
&#xD;
          -  Any clinically significant illness within 4 weeks before screening or surgical or&#xD;
             medical condition (other than Alport syndrome) that could interfere with the subject's&#xD;
             study compliance; confound the study results; impact subject safety; or significantly&#xD;
             alter the absorption, distribution, metabolism, or excretion of drugs;&#xD;
&#xD;
          -  Participation in other interventional clinical studies;&#xD;
&#xD;
          -  Known hypersensitivity to any component of the study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-yan Huang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen-yan Huang, PhD</last_name>
    <phone>+8618964025491</phone>
    <email>huangwenyan@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lei Sun, MD</last_name>
    <phone>+8618817821787</phone>
    <email>sunlei@shchildren.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Children's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-yan Huang, PHD</last_name>
      <phone>+8618964025491</phone>
      <email>huangwenyan@sjtu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hertz JM, Thomassen M, Storey H, Flinter F. Clinical utility gene card for: Alport syndrome - update 2014. Eur J Hum Genet. 2015 Sep;23(9). doi: 10.1038/ejhg.2014.254. Epub 2014 Nov 12.</citation>
    <PMID>25388007</PMID>
  </reference>
  <reference>
    <citation>Daga S, Donati F, Capitani K, Croci S, Tita R, Giliberti A, Valentino F, Benetti E, Fallerini C, Niccheri F, Baldassarri M, Mencarelli MA, Frullanti E, Furini S, Conticello SG, Renieri A, Pinto AM. New frontiers to cure Alport syndrome: COL4A3 and COL4A5 gene editing in podocyte-lineage cells. Eur J Hum Genet. 2020 Apr;28(4):480-490. doi: 10.1038/s41431-019-0537-8. Epub 2019 Nov 21.</citation>
    <PMID>31754267</PMID>
  </reference>
  <reference>
    <citation>Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. doi: 10.1038/s41584-020-0372-x. Epub 2020 Feb 7. Review.</citation>
    <PMID>32034323</PMID>
  </reference>
  <reference>
    <citation>Yang YZ, Chen P, Liu LJ, Cai QQ, Shi SF, Chen YQ, Lv JC, Zhang H. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. BMC Nephrol. 2019 Aug 5;20(1):297. doi: 10.1186/s12882-019-1488-6.</citation>
    <PMID>31382914</PMID>
  </reference>
  <reference>
    <citation>Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis. 2019 Jul;74(1):15-22. doi: 10.1053/j.ajkd.2019.01.026. Epub 2019 Mar 25.</citation>
    <PMID>30922594</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alport Syndrome</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis, Hereditary</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Benazepril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

